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ABSTRACT
Prostate cancer at advanced stages including metastatic and castration-
resistant cancer remains incurable due to the lack of effective therapies. The 
CAMK2N1 gene, cloned and characterized as an inhibitor of CaMKII (calcium/
calmodulin-dependent protein kinase II), has been shown to affect tumorigenesis 
and tumor growth. However, it is still unknown whether CAMK2N1 plays a role in 
prostate cancer development. We first examined the protein and mRNA levels of 
CAMK2N1 and observed a significant decrease in human prostate cancers comparing 
to normal prostate tissues. Re-expression of CAMK2N1 in prostate cancer cells 
reduced cellular proliferation, arrested cells in G0/G1 phases, and induced apoptotic 
cell death accompanied by down-regulation of IGF-1, ErbB2, and VEGF downstream 
kinases PI3K/AKT, as well as the MEK/ERK-mediated signaling pathways. Conversely, 
knockdown of CAMK2N1 had a significant opposite effects on these phenotypes. 
Our analyses suggest that CAMK2N1 plays a tumor suppressive role in prostate 
cancer cells. Reduced CAMK2N1 expression correlates to human prostate cancer 
progression and predicts poor clinical outcome, indicating that CAMK2N1 may serve 
as a biomarker. The inhibition of tumor growth by expressing CAMK2N1 established 
a role of CAMK2N1 as a therapeutic target.
INTRODUCTION
Prostate cancer is one of the most common 
malignancies among men and the second most common 
cause of male cancer-related deaths [1]. The usual 
progression of prostate cancer goes from castration-
sensitive to -resistant, inevitably developing highly 
metastatic properties [2]. Prostate tumors initially 
respond to hormonal intervention therapies, however, 
with androgen-independence emerging, tumors develop 
resistance to anti-androgen therapies [3]. The frontline 
treatments for advanced prostate cancer consist 
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of hormone therapy, chemotherapy, and radiation. 
Unfortunately, limited therapy options are stalling the 
survival rates in patients [4, 5]. 
CAMK2N1 (calcium/calmodulin-dependent 
protein kinase II inhibitor 1, also known as PRO1489), 
a peptide composed of 78-amino acids, was initially 
shown to localize in the cell junction and synapse [6, 
7, 8]. CAMK2N1 functions as a potent and specific 
inhibitor of CaMKII (calcium/calmodulin-dependent 
protein kinase II). CaMKII is a member of the Calcium/
calmodulin (CaM) 2-dependent protein kinase family, 
and is a ubiquitous serine/threonine protein kinase that 
phosphorylates nearly 40 different proteins, including 
enzymes, ion channels, kinases and transcription factors 
[7, 8]. CaMKII signaling plays a role in cell-cycle 
progression by activating MEK/ERK to enhance the 
phosphorylation of p27Kip1[8]. Inhibition of CaMKII 
activity by synthetic agents has been shown to suppress 
cell growth [9]. In addition, CAMK2N1-mediated 
inhibition of CaMKII activity regulates the cell-cycle 
progression in colon cancer cells through de-activation of 
MEK/ERK kinase activity and p27 protein accumulation 
[7, 8]. Currently, it is still unknown whether CAMK2N1 
plays any role in prostate cancer development.
In this study, we performed immunohistochemical 
(IHC) staining using human prostate cancer specimens 
and observed a significant reduction of CAMK2N1 in 
prostate cancer compared to normal tissue. Decreased 
CAMK2N1 expression correlated with more advanced 
stages of prostate cancer. We observed that overexpression 
of CAMK2N1 significantly impaired human prostate 
cancer cell proliferation and tumor growth in vivo, while 
depletion of CAMK2N1 promoted cell proliferation and 
tumor growth. Genome-wide gene profiling revealed 
that CAMK2N1 regulated the expression of key proteins 
associated with cell-cycle progression and apoptosis. 
Taken together, our findings revealed a tumor suppressive 
role for CAMK2N1 and established CAMK2N1 as 
molecular determinant in hormone sensitivity of prostate 
cancer.
RESULTS
Reduced CAMK2N1 expression in human 
prostate cancer
We first analyzed CAMK2N1 protein expression 
in human prostate cancer specimens by performing 
immunohistochemical (IHC) staining. In normal prostate 
tissue, CAMK2N1 showed whole cell distribution with 
stronger staining in the nucleus compared to cytoplasm 
(Fig. 1A). Hyperplastic and normal tissues had similar 
expression levels and distribution patterns (Fig 1A-B). 
However, CAMK2N1 protein levels were decreased in 
cancerous tissues with moderate expression in early stages 
(I /II) and poor expression in advanced stages (III/IV). The 
nuclear CAMK2N1 staining was quantified in human 
prostate tumors (n = 50), hyperplastic tissues (n = 20), and 
normal control specimens (n = 10) (Fig. 1B). Next, we 
analyzed the abundance of CAMK2N1 mRNA in prostate 
cancer tissues compared to matched normal-like control 
from same patient (n = 10) by quantitative RT-PCR (qRT-
PCR) analysis. As shown in Fig. 1C, the mRNA level of 
CAMK2N1 was significantly reduced in prostate cancer 
tissues compared to normal prostate, which is consistent 
with the reduced protein expression in prostate cancer 
cells.
Next, we examined CAMK2N1 mRNA levels 
by qRT-PCR in several most commonly used prostate 
epithelial cells, including AR-negative PC3 and DU145 
cells, AR-positive castration-sensitive LNCaP cell and 
RWPE1, a normal prostate cell line serving as control. 
As shown in Fig. 1D, all prostate cancer cells exhibited 
decreased expression of CAMK2N1, with LNCaP being 
closest to the control. Taken together, these observations 
suggest that the level of CAMK2N1 is reduced in both 
human prostate cancer patient samples and commonly 
used prostate cancer cells. 
CAMK2N1 inhibits prostate cancer cell 
proliferation and cell cycle progression
To determine the functional significance of 
CAMK2N1 in regulating human prostate cancer growth, 
we first analyzed whether CAMK2N1 regulates the 
proliferation of human prostate cancer cells by MTT 
assays. We found that overexpression of CAMK2N1 in 
DU145 and PC3 cells inhibited cellular proliferation (Fig. 
2A-B), and conversely, depletion of CAMK2N1 in DU145 
cells using shRNAs targeting CAMPK2N1 enhanced cell 
proliferation (Fig. 2C). To further analyze the effect of 
CAMK2N1 on cell-cycle progression, FACS analysis was 
conducted. Overexpression of CAMK2N1 increased G0/G1 
cell fraction and reduced the proportion of cells in S-phase 
after 24 hrs post serum induction in serum-starved DU145 
and PC3 cells (Fig. 2D-E, Supplemental Fig. 2A), while 
knockdown of CAMK2N1 in DU145 cells with shRNA 
reduced the proportion of cells in G0/G1 and increased the 
proportion of cells in S-phase (Supplemental Fig. 1A).
To further determine whether CAMK2N1 
inhibits oncogenic growth of prostate cancer cells, we 
performed colony formation assays. Ectopic expression 
of CAMK2N1 inhibited both the number and the size of 
colonies by 30% - 40% (Fig. 2F-K,), while the shRNA-
mediated knockdown of CAMK2N1 enhanced DU145 
colony formation (Supplemental Fig. 1B).
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Figure 1: CAMK2N1 abundance is reduced in human prostate cancer. (A) Representative examples of immunohistochemical 
staining for CAMK2N1 in each of the clinical stages of prostate cancers as indicated. (B) Quantification of CAMK2N1 relative 
immunostaining intensity for each clinical stage of prostate cancers. Data is shown as mean ± SEM for N as indicated in the figure in 
parethesis as shown. (C) CAMK2N1 mRNA determined by quantitative PCR. Comparison was made between normal and tumorous 
prostate samples. (D) QT-PCR analysis of CAMK2N1 expression in prostate cell lines (RWPE1, LNCaP, DU145, PC3).
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CAMK2N1 inhibits prostate tumor growth in vivo 
Encouraged by these observations, we then 
investigated the role of CAMK2N1 in inhibiting 
prostate tumor growth in vivo. DU145 and PC3 cells 
stably transduced with an expression vector encoding 
CAMK2N1 were implanted subcutaneously into immune-
deficient mice. Tumor size was measured every 5 days 
with last measuring performed on day 32 (Fig. 3A, F). 
We observed that that overexpression of CAMK2N1 
significantly reduced both the tumor size (Fig. 3B,G) and 
the tumor weight (Fig. 3C, H). IHC staining demonstrated 
the expression of CAMK2N1 (Fig. 3D, E, I, J). These 
observations suggest that CAMK2N1 negatively regulate 
prostate tumor growth in vivo.
CAMK2N1 induces apoptotic cell death in human 
prostate cancer cells.
Since elevated cell death may also contribute 
to impaired tumor growth, we determined whether 
CAMK2N1 induces apoptosis by Annexin V staining 
and TUNEL assays. Annexin V staining revealed that 
proportion of cells in early and late apoptosis was 
Figure 2: CAMK2N1 inhibits prostate cancer cell proliferation and cell cycle progression. DU145 and PC3 cells stably 
overexpressed or knocked down CAMK2N1. Cells were analyzed for cell proliferation by (A-C) MTT, cell cycle by (D-E) FACS and 
oncogenic growth by (F-K) Colony-forming assay. Data is shown as mean ± SEM for N > 5 separate experiments. 
Oncotarget3615www.impactjournals.com/oncotarget
Figure 3: CAMK2N1 inhibits prostate tumor growth in vivo. (A-J) Serial measurements were conducted every five days of 
DU145 and PC3 tumors stably expressing CAMK2N1, injected into nude mice. The data is shown as mean ± SEM for N>6 separate tumors 
for each group. (A, F) Images of tumors dissected out from the sacrificed mice. (B, G) The tumor size (mm3) versus days of post injection. 
(C, H) Reduction in tumor weight after resection at the end of experiment. (D-E, I-J) IHC staining detected the expression of CAMK2N1 
in DU145 and PC3 tumor tissues of nude mice.
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increased in CAMK2N1 overexpressing DU145 cells 
(Fig. 4A) and PC3 cells (Supplemental Figure 2B). 
TUNEL staining was conducted to assess the effect of 
CAMK2N1 on cell apoptosis in tumor samples from in 
vivo experiment. Similarly, the percentage of apoptotic 
cells was increased in CAMK2N1 overexpressing tumor 
derived from nude mice implanted with DU145 cells (Fig. 
4B). To determine the expression of Bax, Bcl-2, p21, 
and Ki67 in tumor tissues, we conducted IHC staining 
in tumors with over-expressed CAM2KN1. As shown in 
Fig. 4C, tumors overexpressing CAM2KN1 have reduced 
expression of Bcl-2, Ki67 and increased p21 and Bax 
Figure 4: CAMK2N1 induces apoptotic cell death in human prostate cancer cells. DU145 cells stably overexpressed 
CAMK2N1. These cells were analyzed for apoptosis by (A) Annexin V staining. Quantification of colony numbers and sizes were shown 
as mean ± SEM for N>5 separate experiments. (B) TUNEL staining was conducted to assess the effect of CAMK2N1 on cellular apoptosis 
in vivo. The percentage of apoptotic cells was increased in DU145 tumor tissues derived from nude mice. Quantification of TUNEL staining 
was shown as mean ± SEM for N=4 separate experiments. (C) IHC staining detected the expression of Bax, Bcl2, p21 and Ki67 in DU145 
tumor tissue of nude mice. Overexpression of CAM2KN1 in DU145 and PC3 tumor tissue decreased Bcl-2, Ki67 protein expression and 
increased p21, Bax protein expression. Data for quantified IHC was shown as mean ± SEM for N = 4 tumors in each group.
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expression, suggesting that gain of CAM2KN1 promotes 
apoptosis in prostate cancer cells.
CAMK2N1 suppresses IGF-1, ErbB2, VEGF, 
downstream kinase-PI3K/AKT, MEK/ERK, and 
HSP27-mediated signaling pathways in prostate 
cancer cells.
To determine the mechanisms by which CAMK2N1 
functions to inhibit prostate tumor growth, we performed 
genome-wide gene expression analysis using human 
12×135K gene expression array by comparing DU145 
cells with or without CAMK2N1 overexpression (> 
1.5-fold and p < 0.05). Pathway analysis conducted on 
genes differentially regulated by CAMK2N1 revealed 
several up-regulated signaling pathways, including 
pathways that regulate cell-cycle arrest, apoptosis, and 
DNA damage responses (Fig. 5A). This analysis also 
identified several down-regulated pathways, including 
pathways that control cell growth, cell migration, cell 
adhesion, stress response, blood vessel development, and 
cell communication. CAMK2N1 induced the expression 
of genes encoding CDKN1A, BAX, BAD, GADD45A, 
SFN, CAPNS1, CHEK1, CHEK2, CDKN2A, ANAPC11, 
ANAPC5, SMAD2, SMAD3, CDC20, TGFB1, CASP4, 
CASP7, ATF4, and EIF2A, while CAMK2N1 repressed 
the expression of genes including IGF1, AKT1, BCL2, 
VEGF, ERK1, IKBKB, NFKB1, STAT5B, CREB5, 
ERBB2, BMP7, HSP27, CAMK2A, JAK3, PVRL1, 
WNT3A, WNT9A, NFATC1, KLK2, and SPHK2 clusters 
of genes (Fig. 5B). KEGG (Kyoto Encyclopedia of Genes 
and Genomes) analysis identified an interconnected 
network, including five major kinase pathways: IGF1, 
VEGF, ERBB2, MEK/ERK, PI3K/AKT, which are 
involved in cell growth, survival, migration or invasion, 
and angiogenesis (Supplemental Figure 3A). 
To validate the microarray data, we performed 
Western blot and qRT-PCR analyses and focused on a 
subset of genes that are either down-regulated (ErbB2, 
AKT, MEK1, ERK1/2, Bcl-2) or up-regulated (p21, Bax). 
Overexpression of CAM2KN1 in DU145 and PC3 cells 
resulted in decreased ErbB2, MEK1, pMEK1T292, ERK1/2, 
p-ERK1/2, AKT, pAKTser473, Bcl-2, NF-κB protein 
expression and increased p21 and Bax protein expression 
(Fig. 5C-D, Supplemental Figure 2C). Overexpression of 
CAM2KN1 in DU145 tumor tissues resulted in decreased 
ErbB2, AKT1, Bcl-2, NF-κB and AR mRNA levels and 
increased p21, Bax mRNA levels (Figure 5E). Conversely, 
knockdown of CAMK2N1 by shRNA in DU145 cells 
led to an opposite effect on protein expression of these 
genes (Supplemental Figure 1C). Taken together, these 
data showed that CAMK2N1 regulates cell proliferation, 
apoptosis and tumor growth in vivo, likely through the 
functional interactions with these signaling molecules in 
prostate cancer cells. 
DISSCUSSION
In this study, we demonstrated that CAMK2N1 
plays a tumor suppressive role in human prostate 
cancer. CAMK2N1 is significantly reduced in prostate 
cancer compared to benign and normal prostate tissues. 
Reduced CAMK2N1 expression positively correlated 
with prostate tumor progression (stage, TNM). Consistent 
with the expression pattern in normal and malignant 
prostate tissues, CAMK2N1 was expressed at a higher 
level in non-tumorigenic prostate epithelial cells. In 
addition, a moderate expression of CAMK2N1 was 
detected in castration sensitive LNCaP cells, while its 
expression was relatively low in castration-resistant 
prostate cancer DU145 and PC3 cells. Overexpression 
of CAMK2N1 in DU145 and PC3 cells led to the 
inhibition of cell proliferation, accumulation in G0/G1 
phase and the induction of apoptosis, while CAMK2N1 
knockdown promoted S-phase entry after release from 
G0/G1 synchronization and enhanced cell proliferation in 
DU145 cells. 
CAMK2N1 is the specific inhibitor of CaMKII. 
As a ubiquitous serine/threonine protein kinase, CaMKII 
phosphorylates nearly forty different proteins, including 
enzymes, ion channels, kinases and transcription factors 
[7, 8]. In previous studies, CAMKII was involved 
in insulin-induced cell proliferation [10]. CaMKII 
phosphorylates Raf-1 at S338 and participates in ERK 
activation upon different stimuli [11]. Furthermore, 
CAMK2N1-mediated inhibition of CAMKII activity 
caused deactivation of MEK/ERK kinase activity and 
accumulation of p27 protein, which primarily regulates 
the cell cycle progression of colon cancer cells [7, 
8], suggesting a role of CAMK2N1 in tumorigenesis. 
However, the role of CAMK2N1 in cancer has not been 
investigated in more details. PI3K/AKT and MEK/ERK 
signaling pathways have been shown to cooperate in 
prostate cancer progression and the transition to castration 
resistant disease [12]. Inhibition of these signaling 
pathways acts combinatory to suppress the pathway 
activation and inhibit tumor growth, cellular proliferation 
and migration in prostate cancer [13]. Analyses of human 
prostate tumor specimens suggest that PI3K/AKT and 
MEK/ERK signaling pathways are frequently activated 
by IGF-1, ErbB2, and VEGF in prostate tumors [13, 14, 
15], via the phosphorylation, subsequent activation of NF-
κB, Bcl2 protein, and deactivation of p21 and Bad protein. 
Increased activation of the PI3K-Akt-mTORC1 pathway 
is a common aberration in prostate cancer [16]. IGF-1 
acts as an important regulator of growth, survival, and 
metastatic potential in a variety of malignancies and has 
been shown to be involved in prostatic carcinogenesis and 
CRPC [17]. IGF-1 also rapidly potentiates the activation 
of Ca2+/CAMKII channel [18]. In this study, we observed 
that CAMK2N1 suppressed the IGF-1, ErbB2, VEGF 
expression and their downstream kinase-PI3K/AKT, and 
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Figure 5: CAMK2N1 suppresses IGF-1, ErbB2, VEGF, downstream kinase-PI3K/AKT, MEK/ERK and HSP27-
mediated signaling pathways in prostate cancer cells. (A-B) Microarray gene expression analysis was conducted in DU145 cells 
stably overexpressing CAMK2N1 (>1.5-fold and p < 0.05). (A) Functional analysis of differentially expressed genes. Gene Ontology (GO) 
Biological Process (BP) terms were ranked by score (score > 1.3). (B) CAMK2N1 induced and repressed clusters of genes that were chosen 
from the pathways. (C-D) Expression levels of ErbB2, AKT, MEK1, ERK1/2, NFκβ, Bcl-2, BAX, and p21 were determined by Western 
blot in DU145 cells with stably overexpressing CAMK2N1. Similar changes as to those found in the microarray analysis were observed. 
Each figure represents three independent experiments. (E) DU145 tumors stably expressing CAMK2N1, and mRNA levels of ErbB2, Bcl-2, 
NF-κβ, AKT1, AR, p21, and Bax were determined by qRT-PCR. CAMK2N1 decreased ErbB2, BCL-2, NF-κβ, AKT1, AR mRNA levels 
and increased p21, Bax mRNA levels in DU145 tumor tissues. The data is shown as mean ± SEM for N=4 separate tumors for each group.
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MEK/ERK-mediated signaling pathways, which were 
critical for cell proliferation and survival. Furthermore, 
CAMK2N1 induced cell cycle regulatory kinases, p21, 14-
3-3, Chk1, Chk2, possibly accounting for the G0/G1 arrest. 
CAMK2N1 also induced apoptosis regulatory kinases 
including Bax/Bcl2, Bad, caspase4, caspase7, explaining 
how CAMK2N1 enhanced cell apoptosis. Collectively, 
results from our study revealed the tumor suppressive role 
of CAMK2N1 in prostate cancer. 
In summary, we demonstrated that CAMK2N1 
expression was reduced in prostate cancer. Increased 
CAMK2N1 expression suppressed cell proliferation, 
survival and tumor growth in vivo. These data suggested 
that CAMK2N1 plays an important role in the progression 
of prostate cancer. This study confirmed a value of 
CAMK2N1 in predicting patient’s responsiveness, in 
addition also established a potential of CAMK2N1 as 
a therapeutic target. Re-expression of CAMK2N1 in 
prostate cancer may provide clinical benefits to patients; 
however, further studies are warranted to determine the 
molecular mechanisms link between CAMK2N1 and 
androgen receptor signaling in prostate cancer.
MATERIALS AND METHODS
Cell culture, Plasmid construction, Reporter 
genes, Expression vectors, and DNA transfection
Human prostate cancer DU145 and PC3 cells were 
obtained from ATCC and maintained in DMEM medium 
(Invitrogen) supplemented with 10% fetal bovine serum. 
The CAMK2N1 human cDNA clone was purchased from 
OriGene Technologies and subcloned into the EcoRI/
XhoI site of MSCV-IRES-GFP (Addgen) retroviral vector. 
pGIPZ Vector, pGIPZ-shCAMK2N1(V3LHS-315689, 
5’-TCAATAACAACCCGCTTGC-3’), were purchased 
from Thermo Scientific. DU145 and PC3 cells infected 
with MSCV-IRES-GFP, MSCV-CAMK2N1-IRES-GFP, 
pGIPZ-Vector, pGIPZ-shCAMK2N1. GFP positive cells 
were selected by FACS (Fluorescence Activated cell 
sorter). 
Colony Formation Assays 
 Cells were plated in triplicates in 3 ml of 0.3% 
agarose (sea plaque) in complete growth medium overlaid 
on 0.5% agarose base, also in complete growth medium. 
Two weeks post cell seeding, colonies were visualized 
after staining with 0.04% crystal violet in methanol for 
1-2 hrs. The colonies more than 50 µm in diameter were 
counted using an Omnicon 3600 image analysis system. 
Cell Proliferation Assays
2×103 stable cells were seeded in 96-well plate in 
normal growth medium, and cell growth was measured 
daily by MTT assays using 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide. 
Cell Cycle and Apoptosis Analysis 
Cell cycle parameters were determined by flow 
cytometry. Stable cells were processed by standard 
methods using propidium iodide staining of nuclear DNA. 
Each sample was analyzed by flow cytometry with a 
FACScan Flow Cytometer (Becton-Dickinson Biosciences, 
Mansfield, MA) using a 488 nm laser. Histograms were 
analyzed for cell cycle compartments using ModFit 
version 2.0 (Verity Software House, Topsham, ME). A 
minimum of 20,000 events were collected to maximize 
statistical validity of the compartmental analysis. The PE-
Annexin-V Apoptosis Detection Kit (BD Biosciences) was 
used to detect apoptosis by flow cytometry [19].
Western Blot
Western blots were performed on DU145, PC3 and 
LNCaP cells as indicated. Cells were pelleted and lysed 
in buffer (50 mM HEPES, pH 7.2, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1% Tween 20) 
supplemented with a protease inhibitor cocktail (Roche 
Diagnostics, Mannheim, Germany). Antibodies used for 
Western blots were: anti-CAMK2N1 (D-14) [7, 8] and 
anti-AR (H-280) (Santa Cruz). 
Microarray and Cluster Assays
DNA-free total RNA isolated from DU145 cells 
expressing CAMK2N1 was used to probe Human 
12×135K gene expression array (KangChen Bio-Tech). 
RNA quality was determined by gel electrophoresis. 
Probe synthesis and hybridization were performed in 
NimbleGen Hybridization System. Analysis of the arrays 
was performed using Agilent GeneSpring GX v11.5.1 
software. Arrays were extracted and normalized using 
NimbleScan v2.5 software, and the P-value of 0.05 was 
applied as a statistical criteria for differentially expressed 
genes. These genes were then grouped using hierarchical 
clustering with “complete” agglomeration, and each 
cluster was further analyzed based upon the known 
function of the genes contained in the cluster. Expression 
profiles were displayed using Treeview. Classification 
and clustering for pathway level analysis were performed 
by using gene sets ASSESS (Analysis of Sample Set 
Enrichment Scores), available online. ASSESS provides 
a measure of enrichment of each gene set in each sample. 
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Gene set enrichment was dependent on a concordance 
of at least two samples within the replicates that were 
contrast between phenotypes [20, 21].
RNA Isolation and Quantitative Real-time PCR 
(qRT-PCR) Assays 
Total RNA was isolated and reversely transcribed 
to cDNA using TRIzol reagent (Invitrogen) and iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, 
CA), respectively, according to the manufacturer’s 
instructions [22]. qRT-PCR was carried out in Bio-Rad 
CFX96 Real-Time PCR Detection System with iQ SYBR 
Green Supermix (Bio-Rad). Relative gene expression was 
normalized to 18s rRNA and calculated by using the 2-∆∆Ct 
method. 
Immunohistochemistry
Immunohistochemical analysis of human prostate 
cancer was conducted using a polyclonal CAMK2N1 
antibody [7, 8]. Human prostate cancer tissue arrays were 
purchased from Biomax, US. 
Nude Mice Study
2 × 106 DU145 cells and PC3 cells expressing 
CAMK2N1 were implanted subcutaneously into 
4-6-week-old athymic female nude mice purchased from 
Beijing HFK Bio-Technology.co., LTD. Tumor growth 
was measured using a digital caliper every 5 days for 4-5 
weeks. Tumor weight was measured when mice were 
sacrificed on day 32 after cell implantation. 
ACKNOWLEDGEMENTS
This work was supported by grant from National 
Natural Sciences Foundation of China (No. 81001133). 
Microarray experiments were performed by KangChen 
Bio-tech, Shanghai, China. The authors thank Xuetao Cao 
to provide CAMK2N1 plasmid and antibody information. 
CONFLICT OF INTEREST 
The authors have no conflicts of interest to disclose.
REFERENCES
1 Karavitakis M, Winkler MH, Abel PD, Hazell S, Ahmed 
HU. Focal therapy for prostate cancer: opportunities and 
uncertainties. Discov Med. 2011; 12(64): 245-55.
2 So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms 
of the development of androgen independence in prostate 
cancer. World J Urol. 2005; 23(1): 1-9.
3 Devlin HL, Mudryj M. Progression of prostate cancer: 
multiple pathways to androgen independence. Cancer Lett. 
2009; 274(2): 177-186.
4 Mohla S, Stearns V, Sathyamoorthy N, Rosenfeld MG., 
Nelson P. The biology of hormone refractory breast and 
prostate cancer: An NCI workshop report. Cancer Biol 
Ther. 2009; 8(21): 1975-1985.
5 Bhandari MS, Petrylak DP, Hussain M. Clinical trials in 
metastatic prostate cancer--has there been real progress in 
the past decade. Eur J Cancer. 2005; 41(6): 941-953.
6 Chang BH, Mukherji S, Soderling TR. Characterization of 
a calmodulin kinase II inhibitor protein in brain. Proc Natl 
Acad Sci U S A .1998; 95(18): 10890-10895.
7 Zhang J, Li N, Yu J, Zhang W, Cao X. Molecular cloning 
and characterization of a novel calcium/calmodulin-
dependent protein kinase II inhibitor from human dendritic 
cells. Biochem Biophys Res Commun. 2001; 285(2): 229-
234.
8 Ling KH, Hewitt CA, Beissbarth T, Hyde L, Cheah PS, 
Smyth G.K, Tan SS, Hahn CN, Thomas T, Thomas PQ, 
Scott HS. Spatiotemporal regulation of multiple overlapping 
sense and novel natural antisense transcripts at the Nrgn and 
Camk2n1 gene loci during mouse cerebral corticogenesis. 
Cereb Cortex. 2001; 21(3): 683-697
9 Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, 
Koteliansk VE, Glover RA, Cohen MB. Calcium/
calmodulin dependent kinase II plays an important role in 
prostate cancer cell survival. Cancer Biol Ther. 2007; 6(5), 
732-742.
10 Franklin RA1, McCubrey JA. The involvement of CaM-
KII in insulin induced cell proliferation. Cell Cycle. 2009; 
8(13):1979. 
11 Salzano M1, Rusciano MR, Russo E, Bifulco M, Postiglione 
L, Vitale M. Calcium/calmodulin-dependent protein kinase 
II (CaMKII) phosphorylates Raf-1 at serine 338 and 
mediates Ras-stimulated Raf-1 activation. Cell Cycle. 2012; 
11(11):2100-2106. 
12 Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, 
Shen MM, Abate-Shen C. Combinatorial activities of Akt 
and B-Raf/Erk signaling in a mouse model of androgen-
independent prostate cancer. Proc Natl Acad Sci U S A. 
2006; 103(39): 14477-14482. 
13 Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, 
Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-
Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERK 
MAPK signaling inhibits hormone-refractory prostate 
cancer in a preclinical mouse model. J Clin Invest. 2008; 
118(9): 3051-3064. 
14 Dillin A, Crawford DK, Kenyon C. Timing requirements 
for insulin/IGF-1 signaling in C. elegans. Science. 2000; 
298(5594): 830-834.
15 Shin-Kang S, Ramsauer VP, Lightner J, Chakraborty K, 
Stone W, Campbell S, Reddy SA, Krishnan K.Tocotrienols 
Oncotarget3621www.impactjournals.com/oncotarget
inhibit AKT and ERK activation and suppress pancreatic 
cancer cell proliferation by suppressing the ErbB2 pathway. 
Free Radic Biol Med. 2011; 51(6): 1164-1174. 
16 Ellis L1, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari 
G, Godoy A, Pili R. Combinatorial antitumor effect of 
HDAC and the PI3K-Akt-mTOR pathway inhibition in a 
Pten defecient model of prostate cancer. Oncotarget. 2013 
Dec;4(12):2225-36.
17 Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, 
Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-
like growth factor-I and prostate cancer risk: a prospective 
study. Science. 1998; 279(5350): 563-566.
18 Gao L, Blair LA, Salinas GD, Needleman LA, Marshall J. 
Insulin-like growth factor-1 modulation of CaV1.3 calcium 
channels depends on Ca2+ release from IP3-sensitive stores 
and calcium/calmodulin kinase II phosphorylation of the 
alpha1 subunit EF hand. J Neurosci. 2006; 26(23): 6259-
6268.
19 Liu M, Ju X, Willmarth NE, Casimiro MC, Ojeifo J, 
Sakamaki T, Katiyar S, Jiao X, Popov VM, Yu Z, Wu K, 
Joyce D, Wang C, Pestell RG.. Nuclear factor-kappaB 
enhances ErbB2-induced mammary tumorigenesis and 
neoangiogenesis in vivo. Am J Pathol. 2009; 174(5): 1910-
1920. 
20 Chen K, Wu K, Cai S, Zhang W, Zhou J, Wang J, Ertel 
A, Li Z, Rui H, Quong A, Lisanti MP, Tozeren A, Tanes 
C, Addya S, Gormley M, Wang C, McMahon SB, Pestell 
RG.. Dachshund binds p53 to block the growth of lung 
adenocarcinoma cells. Cancer Res. 2013; 73(11): 3262-
3274. 
21 Chen K, Wu K, Gormley M, Ertel A, Wang J, Zhang W, 
Zhou J, Disante G., Li Z, Rui H, Quong, AA, McMahon 
SB, Deng H, Lisanti MP, Wang C, Pestell RG.. Acetylation 
of the cell-fate factor dachshund determines p53 binding 
and signaling modules in breast cancer. Oncotarget. 2013; 
4(6), 923-935.
22 Giorno F, Wolters-Arts M, Grillo S, Scharf KD, Vriezen 
WH, Mariani C. Developmental and heat stress-regulated 
expression of HsfA2 and small heat shock proteins in 
tomato anthers. J Exp Bot. 2010; 61(2): 453–462.
